A086890 Stock Overview
A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ISU Abxis Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,450.00 |
| 52 Week High | ₩8,410.00 |
| 52 Week Low | ₩5,250.00 |
| Beta | 0.76 |
| 1 Month Change | -5.84% |
| 3 Month Change | 11.40% |
| 1 Year Change | -9.79% |
| 3 Year Change | -60.31% |
| 5 Year Change | -11.03% |
| Change since IPO | -29.89% |
Recent News & Updates
Shareholder Returns
| A086890 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -4.6% | -2.7% | -3.1% |
| 1Y | -9.8% | -1.2% | 1.5% |
Return vs Industry: A086890 underperformed the KR Biotechs industry which returned -1.2% over the past year.
Return vs Market: A086890 underperformed the KR Market which returned 1.5% over the past year.
Price Volatility
| A086890 volatility | |
|---|---|
| A086890 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A086890 has not had significant price volatility in the past 3 months.
Volatility Over Time: A086890's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Yeob Hwang | www.abxis.com |
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.
ISU Abxis Co., Ltd. Fundamentals Summary
| A086890 fundamental statistics | |
|---|---|
| Market cap | ₩228.63b |
| Earnings (TTM) | -₩8.09b |
| Revenue (TTM) | ₩64.06b |
3.6x
P/S Ratio-28.3x
P/E RatioIs A086890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086890 income statement (TTM) | |
|---|---|
| Revenue | ₩64.06b |
| Cost of Revenue | ₩21.49b |
| Gross Profit | ₩42.57b |
| Other Expenses | ₩50.65b |
| Earnings | -₩8.09b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -228.21 |
| Gross Margin | 66.45% |
| Net Profit Margin | -12.63% |
| Debt/Equity Ratio | 49.8% |
How did A086890 perform over the long term?
See historical performance and comparison